Preclinical studies on antineoplaston A10 injections.

Area of Science:

• Pharmaceutical Chemistry
• Organic Chemistry
• Biochemistry

Background:

• Antineoplaston A10 (3-phenylacetylamino-2, 6-piperidinedione) exhibits poor water solubility, limiting its use in injectable formulations.
• Conversion to a sodium salt is necessary for preparing Antineoplaston A10 injections.

Purpose of the Study:

• To investigate the hydrolysis of Antineoplaston A10 during salt formation.
• To identify the degradation products and assess their potential role in the compound's anticancer activity.
• To develop a stable and non-toxic injectable formulation.

Main Methods:

• Basic and acid hydrolysis of Antineoplaston A10 under varying conditions.
• Identification of hydrolysis products using analytical techniques.
• Preparation and chronic toxicity testing of a novel injectable formulation.

Main Results:

• Basic hydrolysis of Antineoplaston A10 yielded two main components, identified as phenylacetylglutamine and phenylacetylisoglutamine in a consistent 4:1 ratio.
• Acid hydrolysis at 110°C resulted in complete hydrolysis.
• A similar 4:1 ratio of these products was observed during hydrolysis in simulated pancreatic juice.
• The developed formulation of Antineoplaston A10 injections (100 mg/ml as a 4:1 mixture of sodium salts) showed no significant toxicity in a one-year chronic toxicity study in mice.

Conclusions:

• Antineoplaston A10 undergoes hydrolysis to form phenylacetylglutamine and phenylacetylisoglutamine.
• These degradation products may contribute to the therapeutic effects of Antineoplaston A10.
• A stable, non-toxic injectable formulation of Antineoplaston A10, as a mixture of its sodium salts, has been successfully developed.